LIGAND PHARMACEUTICALS INC【LGND】

時価総額

$38.6億

PER

臨床開発支援を行うバイオ医薬品関連の有力企業。技術ライセンスと資金提供、ロイヤリティ収益化やCaptisolなどの経済権を展開。2022年11月の抗体発見事業スピンオフと2023年10月の75百万ドルリボ契約などの資本・再編イベント。米国・欧州中心に展開。

株価業績

サマリーテーブルに戻る

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	10	-1	11	12	257	-2	13	143	629	-3	57	-33	52	-4
Gain on sale of Pelican	-	-	-	-	-	-	-	-	-	17	-	-	2	-
Change in estimated fair value of contingent liabilities	-1	-2	-4	-5	-5	-3	-3	-3	0	-1	37	1	0	-1
Depreciation, Depletion and Amortization	3	3	3	3	3	11	12	15	18	26	51	52	37	35
Gain from short-term investments	-	-	-	-	-	-	-	-	-	-17	-4	29	46	68
Amortization/accretion of premium (discount) on investments, net	-	-	-	-	-	-0	0	5	10	-1	-0	-0	1	1
Amortization of debt discount and issuance fees	-	-	-	-	10	11	12	44	30	23	17	1	0	0
Loss (gain) on derivative instruments	-	-	-	-	-	-	-	-	-	-	-	-	0	-20
Gain on debt extinguishment	-	-	-	-	-	-	-	-	-	-	-7	4	-	-
Non-cash income from financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	-	5
CECL adjustment to financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-4
Impairment loss of financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	-	31
Lease amortization expense	-	-	-	-	-	-	-	-	-	-	-	6	2	2
Share-based compensation	3	4	6	11	12	19	25	21	25	31	39	60	26	41
Losses from equity method investment in Primrose Bio	-	-	-	-	-5	-23	-2	42	3	-	-	-	-2	-13
Fair value adjustment to Primrose Bio securities investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-26
Deferred income taxes, net	13	1	-0	-0	220	-11	-45	-30	-75	19	9	-21	-12	16
Other	-	-	-	-	0	-	-	-	-1	3	2	0	1	8
Accounts receivable, net	4	-2	-2	10	-6	9	8	30	-25	26	29	-55	3	6
Inventory	-1	-1	-1	-4	0	0	1	3	2	18	0	-12	11	-10
Other economic rights	-	-	-	-	-	-	-	-	-	-	-	-	5	-
Accounts payable and accrued liabilities	-12	-5	-3	-3	-4	-2	-2	-5	-7	-1	3	-3	-5	14
Income taxes receivable and payable	-	-	-	-	-	-	-	-	11	-9	4	-2	2	-2
Deferred revenue	-	-	-	-	-	-	-	-1	-	29	-18	-6	0	-1
Other assets and liabilities	-	-	-	-	-	-	-	-	-	-	-	-6	10	-1
Net cash provided by operating activities	-1	0	21	21	42	63	94	194	-29	55	79	138	50	97
Acquisition of financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	-	18
Proceeds from financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	-	7
Purchases of property and equipment	0	1	0	0	0	2	2	1	3	4	9	18	4	2
Purchases of short-term investments	10	-	-	-	166	164	254	1,434	2,357	423	181	51	127	226
Proceeds from sale of short-term investments	19	10	-	2	16	25	87	132	536	395	154	210	149	229
Proceeds from maturity of short-term investments	-	-	-	-	57	119	110	893	1,495	644	67	25	45	33
Cash paid for equity method investment	-	-	-	-	-	-	-	-	-	-	-	-	15	1
Cash paid for Palvella notes receivable	-	-	-	-	-	-	-	-	-	-	-	-	-	3
Cash paid for Novan acquisition, net of restricted cash received	-	-	4	1	4	93	27	6	12	405	-	-	10	-
Cash paid for the Agenus transaction	-	-	-	-	-	-	-	-	-	-	-	-	-	75
Cash paid for Apeiron acquisition, net of cash received	-	-	-	-	-	-	-	-	-	-	-	-	-	92
Cash paid for InvIOs investment	-	-	-	-	-	-	-	-	-	-	-	-	-	4
Proceeds from Derivative Instrument, Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	7
Other	0	0	0	-0	-	-	-	-	5	-2	1	1	-	-
Net cash used in (provided by) investing activities	-25	1	-5	-2	-113	-143	-84	-423	467	232	31	164	-12	-144
Proceeds from Issuance of Common Stock	0	5	-	-	-	-	-	-	-	-	-	-	-	37
Net cash transferred to OmniAb at OmniAb Separation	-	-	-	-	-	-	-	-	-	-	-	2	-	-
Repayment at maturity/repurchase of 2023 Notes	-	10	20	9	-	-	-	218	27	222	156	261	77	-
Payments under finance lease obligations	-	-	-	-	-	-	-	-	-	10	9	0	0	0
Cash paid for transaction costs related to OmniAb Transactions	-	-	-	-	-	-	-	-	-	-	-	7	-	-
Cash paid for debt issuance costs	-	-	-	6	-	-	-	17	-	-	-	-	1	0
Proceeds from bond hedge settlement	-	-	-	-	-	-	-	440	12	-	19	0	-	-
Proceeds from Stock Options Exercised	-	1	3	5	9	6	5	20	3	3	34	3	22	66
Taxes paid related to net share settlement of equity awards	-	-	-	-	-	1	10	4	4	1	6	8	5	5
Payments to CVR Holders	-	-	-	-	-	-	-	0	3	2	1	2	-	-
Net cash provided by (used) in financing activities	30	4	-16	130	8	2	-8	329	-485	-311	-138	-276	-60	97
Effect of exchange rate changes on cash and cash equivalents	-	-	-	-	-	-	-	-0	0	-	-	-	-	-1
Net increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	49
Interest paid	-	-	-	-	-	-	-	2	6	4	3	1	0	0
Taxes paid	0	-	0	0	0	0	0	0	104	2	4	12	9	19
Net cash paid for acquisitions	-	-	4	1	4	93	27	6	12	405	-	-	10	-
Accrued Primrose transaction costs	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Addition of right-of-use assets and lease liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	2
Accrued royalty from financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Accrued purchases of financial royalty assets	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Accrued debt issuance costs	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accrued fixed asset purchases	-	-	-	-	-	-	-	-	0	0	2	2	-	0
Unrealized Gain (Loss) on Investments	-	-	3	4	3	-1	0	0	0	-0	-0	-0	0	0